靶向STAT蛋白的抑制剂在淋巴瘤治疗中的研究进展  

Research progress on STAT protein inhibitors in the treatment of lymphoma

作　　者：邓绮虹 王峥 邓贤明[1] 李莉[1] DENG Qi-hong;WANG Zheng;DENG Xian-ming;LI Li(State-Province Joint Engineering Laboratory of Targeted Drugs from Natural Products,School of Life Sciences,Xiamen University,Xiamen 361102,China;College of Food and Biological Engineering,Jimei University,Xiamen 361021,China)

机构地区：[1]厦门大学生命科学学院,天然产物源靶向药物国家地方联合工程实验室,福建厦门361102 [2]集美大学食品与生物工程学院,福建厦门361021

出　　处：《药学学报》2021年第3期703-710,共8页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(82073874)。

摘　　要：信号转导和转录激活蛋白(signal transducer and activator of transcription, STAT)家族在多种恶性淋巴瘤中普遍存在异常激活和突变,其抑制剂的研究发现与临床应用成为淋巴瘤的一个重要治疗策略。本文介绍了STATs蛋白在多种恶性淋巴瘤中的异常激活突变,并着重综述了靶向STATs蛋白的最新筛选策略及其在淋巴瘤治疗中的临床应用研究,为STATs抑制剂的进一步研发提供借鉴。The abnormal activation and mutation of signal transducer and activator transcription(STAT)proteins has been implicated in multiple lymphomas. The research discovery and clinical application of STATs inhibitors have become an important strategy for treating lymphoma. This review introduces the abnormal activation and mutation of STATs in multiple malignant lymphomas, and focuses on reviewing the latest screening strategies targeting STATs and its clinical application in the treatment of lymphoma, providing references for the further development of STATs inhibitors.

关 键 词：淋巴瘤 STAT转录因子 抗肿瘤药 药物筛选 靶向治疗 

分 类 号：R733.4[医药卫生—肿瘤]